Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by futuregainson Jul 26, 2020 8:59am

204 Views

Post# 31320355

Found this article concerning intellectual property rights

for repurposed drugs. Very good read indeed. AGN has a plan.

https://www.lexology.com/library/detail.aspx?g=f19d1544-217e-444f-8c36-06a30e0b81f7#:~:text=Repurposing%20drugs%20is%20further%20incentivized%20through%20the%20granting,new%2C%20useful%2C%20and%20non-obvious%20invention%20for%2020%20years.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing